Tesamorelin is a full-length 44-amino acid human GHRH analogue stabilized at its N-terminus with a trans-3-hexenoic acid group to prevent DPP-4 cleavage while preserving native pituitary GHRH receptor kinetics.
Scientific Profile & Research Key Points: Tesamorelin
Tesamorelin is a full-length 44-amino acid human GHRH analogue stabilized at its N-terminus with a trans-3-hexenoic acid group to prevent DPP-4 cleavage while preserving native pituitary GHRH receptor kinetics.
Active Batch Release Specifications (Lot SL-2026-162)
Analytical release verification for current Tesamorelin (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-162 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water (1.0–2.0 mL)
Temperature & Stability
Store lyophilized at -20°C; refrigerate solution at 2°C–8°C for up to 21 days.
Tesamorelin — Technical Questions & Answers
What is the molar concentration when reconstituting Tesamorelin (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of Tesamorelin (MW 5135.77 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 0.49 mM (487 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does Tesamorelin's counterion stoichiometry affect assay mass calculations?
Tesamorelin (CAS 218949-48-5, formula C221H366N72O67S) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify Tesamorelin Lot SL-2026-162 and what pathway does it target?
Lot SL-2026-162 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 5135.77 g/mol. In preclinical literature, Tesamorelin targets Pituitary GHRH Receptor (full-length stabilized GHRH 1-44 analogue) (Falutz J. et al., N Engl J Med (2007) — Metabolic effects of trans-3-hexenoyl GHRH(1-44) analogue Tesamorelin (PMID: 18057338)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
CJC-1295, Ipamorelin, and Sermorelin: GHRH Analogues vs Ghrelin Receptor Agonists
A deep dive into somatotropic axis stimulation. Comparing GHRH receptor binding, DAC modification kinetics, ghrelin/GHS-R1a agonism, and pulsatile growth hormone secretion.
Gonadorelin, HCG, HMG and Kisspeptin: Mapping the Hypothalamic-Pituitary-Gonadal Axis
A comparative map of the HPG axis: GnRH receptor agonism (Gonadorelin), LH receptor mimetics (HCG), combined FSH/LH activity (HMG), and upstream GPR54 activation (Kisspeptin-10).
Human Growth Hormone (191aa): Somatropin Structure, Isoforms, and SEC-HPLC Analysis
A deep analysis of authentic 191-amino acid Somatropin vs 192-amino acid Somatrem. Size-exclusion chromatography (SEC), deamidation artifacts, and mass confirmation.
Related GH Secretagogues & Growth Factors Compounds
View category →